Epidemiology and risk factors of migraine and TTH in Sudanese health sciences students [0.03%]
苏丹卫生科学专业学生偏头痛和紧张型头痛的流行病学及危险因素
Rashid Mohamed Hassan Nasr,Jaber Hamad Jaber Amin,Mustafa Mohamed Majdeldien Mustafa et al.
Rashid Mohamed Hassan Nasr et al.
Site-specific pain dynamics: associations between accelerometer-measured physical activity patterns and pain in older adults [0.03%]
老年人加速度计测量的体育活动模式与疼痛之间的关联研究
Lingjie Fan,Junhan Zhao,Xiyue Wang et al.
Lingjie Fan et al.
Background: Physical activity (PA) has emerged as a promising non-pharmacological intervention for pain management, the relationship between objectively measured PA patterns and multi-site pain remains poorly understood. ...
5.0 T MRI reveals characteristic alterations in visual and somatomotor networks associated with migraine chronification: a single-center prospective cohort study [0.03%]
5.0T磁共振成像显示视觉和躯体感觉运动网络在偏头痛慢性发作中的特征性变化：单中心前瞻性队列研究
Jiaming Lu,Haiyun Han,Huanyu Ni et al.
Jiaming Lu et al.
The P2Y13 receptor-mediated microglial morphological transformation through the p38MAPK signaling pathway contributes to central sensitization in a murine model of chronic migraine [0.03%]
小鼠慢性偏头痛模型中P2Y13受体介导的小胶质细胞形态转化通过p38MAPK信号通路参与中枢敏化形成的作用机制研究
Yingjie Yang,Suya Sun,Pengtao Qin et al.
Yingjie Yang et al.
Background: Central sensitization is a crucial pathophysiological mechanism of chronic migraine (CM), and neuroinflammation mediated by activated microglia contributes significantly to the development of central sensitiza...
Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: a real-world assessment [0.03%]
载入、更换及注射降钙素基因相关肽药物抑制剂的持久性及其对医疗保健使用的影响：基于真实世界证据的评估
Cristiano S Moura,Jason R Randall,Scott Klarenbach et al.
Cristiano S Moura et al.
Background: Migraine is a prevalent and disabling condition affecting one billion people worldwide. calcitonin gene-related peptide (CGRP) inhibitors have transformed migraine management. We describe real-world trends in ...
Correction: Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment [0.03%]
对预防性使用CGRP靶向治疗的患者感染风险增加的纠正意见——一项meta分析和临床效果评估
Marcin Straburzyński,Daria Kopyt,Karol Marschollek et al.
Marcin Straburzyński et al.
Published Erratum
The journal of headache and pain. 2025 Dec 12;26(1):286. DOI:10.1186/s10194-025-02245-3 2025
L3MBTL2 as a novel therapeutic target for trigeminal neuralgia: evidence from integrated TWAS, multi-tissue MR, and experimental validation [0.03%]
L3MBTL2作为三叉神经痛新治疗靶点的证据：来自整合TWAS、多组织MR和实验验证的证据
Hongwei Wang,Min Huang,Yi Huang et al.
Hongwei Wang et al.
Background: Trigeminal neuralgia (TN) is a neurological disorder affecting the maxillofacial region. Current treatment relies on pharmacotherapy and invasive interventions; however, the growing prevalence of drug-resistan...
Trigeminal ganglion interferon-γ signaling drives orofacial neuropathic pain in rats [0.03%]
大鼠三叉神经节干扰素-γ信号驱动口腔面部神经痛
Momoyo Kobayashi,Akiko Okada-Ogawa,Yukinori Tanaka et al.
Momoyo Kobayashi et al.
Background: Chronic neuropathic pain, particularly in the orofacial region, markedly reduces quality of life. Peripheral trigeminal nerve injury activates satellite glial cells (SGCs) in the trigeminal ganglion (TG), whic...
Expression of melatonin receptors in trigeminal and sphenopalatine ganglia: potential targets for primary headache disorders [0.03%]
三叉神经和蝶腭神经节的褪黑素受体表达：原发性头痛疾病潜在作用靶点
Aida Maddahi,Jacob C A Edvinsson,Lars Edvinsson et al.
Aida Maddahi et al.
Background: Primary headache disorders such as migraine and cluster headache exhibit circadian and circannual variations in attack onset. Melatonin plays a central role in regulating biological rhythms and likely influenc...
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention [0.03%]
一项为期24周、开放标签的4期研究，用于评估75 mg利美普郎一日一次给药预防发作性偏头痛的安全性和耐受性
Jeremias Antinew,Robert J Fountaine,Vittorio Loprinzo et al.
Jeremias Antinew et al.
Background: Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist approved in adults for acute treatment of migraine (with or without aura) and preventive treatment of episodic migraine (EM). ...